These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 9276200

  • 21. L-dopa slows the progression of familial parkinsonism.
    Gwinn-Hardy K, Evidente VG, Waters C, Muenter MD, Hardy J.
    Lancet; 1999 May 29; 353(9167):1850-1. PubMed ID: 10359414
    [No Abstract] [Full Text] [Related]

  • 22. Dysphagia in Parkinson's disease is responsive to levodopa.
    Sutton JP.
    Parkinsonism Relat Disord; 2013 Mar 29; 19(3):282-4. PubMed ID: 23333537
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study.
    Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ.
    Brain; 2007 Aug 29; 130(Pt 8):2123-8. PubMed ID: 17586867
    [Abstract] [Full Text] [Related]

  • 25. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Cerasa A, Salsone M, Morelli M, Pugliese P, Arabia G, Gioia CM, Novellino F, Quattrone A.
    Parkinsonism Relat Disord; 2013 Oct 29; 19(10):883-8. PubMed ID: 23769805
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Factors affecting levodopa effects in Parkinson's disease.
    Ogawa N.
    Acta Med Okayama; 2000 Jun 29; 54(3):95-101. PubMed ID: 10925733
    [Abstract] [Full Text] [Related]

  • 30. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa.
    Tan A, Salgado M, Fahn S.
    Mov Disord; 1996 Mar 29; 11(2):214-6. PubMed ID: 8684394
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
    Aaltonen H, Kilkku O, Heinonen E, Mäki-Ikola O.
    BMJ; 1998 Dec 05; 317(7172):1586-7. PubMed ID: 9890764
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P, Hernández B, Ricart J, FAST Study Group.
    Neurologia; 2014 Apr 05; 29(3):153-60. PubMed ID: 23465686
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers.
    Pramstaller PP, Schlossmacher MG, Jacques TS, Scaravilli F, Eskelson C, Pepivani I, Hedrich K, Adel S, Gonzales-McNeal M, Hilker R, Kramer PL, Klein C.
    Ann Neurol; 2005 Sep 05; 58(3):411-22. PubMed ID: 16130111
    [Abstract] [Full Text] [Related]

  • 40. Levodopa for the treatment of Parkinson's disease.
    Lewitt PA.
    N Engl J Med; 2008 Dec 04; 359(23):2468-76. PubMed ID: 19052127
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.